Rezolute earnings release, May 12, 2026
Rezolute
Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 12,
2026 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2026.
Congenital Hyperinsulinism (HI)
Tumor HI
Third Quarter Fiscal 2026 Financial Results
Cash, cash equivalents and investments in marketable securities were $120.3 million as of March 31, 2026, compared with $167.9 million as of June 30, 2025.
Research and development (R&D) expenses were $11.4 million for the third quarter of fiscal 2026, compared with $15.3 million for the same period a year ago. The decrease from fiscal year 2025 to fiscal year 2026 was primarily due to (i) decreased manufacturing costs for ersodetug and (ii) decreased clinical trial activities. R&D expenses include $1.9 million of share-based compensation expense for the third quarter of fiscal 2026, compared with $0.9 million for the same period a year ago.
General and administrative (G&A) expenses were $6.0 million for the third quarter of fiscal 2026, compared with $4.7 million for the same period a year ago. The increase was primarily attributable to increased employee-related stock-based compensation expense, partially offset by a decrease in professional fees. G&A expenses include $2.5 million of share-based compensation expense for the third quarter of fiscal 2026, compared with $1.0 million for the same period a year ago.
Net loss was $16.2 million for the third quarter of fiscal 2026 compared with a net loss of $18.9 million for the same period a year ago.
About Ersodetug
Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from the pancreas, it has the potential to be universally effective at treating hypoglycemia due to any congenital or acquired form of HI.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com.
Financial statements
Income Statement
Three Months Ended — (in thousands, except per share data)
| Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 | Nine Months Ended – March 31, – 2026 | Nine Months Ended – March 31, – 2025 | ||
|---|---|---|---|---|---|
| Operating expenses: | Research and development | 11,412 | 15,283 | 38,909 | 40,664 |
| Operating expenses: | General and administrative | 5,954 | 4,740 | 22,495 | 13,380 |
| Operating expenses: | Total operating expenses | 17,366 | 20,023 | 61,404 | 54,044 |
| Operating expenses: | Loss from operations | -17,366 | -20,023 | -61,404 | -54,044 |
| Operating expenses: | Non-operating income, net | 1,195 | 1,109 | 4,309 | 4,022 |
| Operating expenses: | Net loss | -16,171 | -18,914 | -57,095 | -50,022 |
| Operating expenses: | Basic and diluted net loss per common share | -0.16 | -0.27 | -0.55 | -0.72 |
| Operating expenses: | Shares used to compute basic and diluted net loss per common share | 104,040 | 70,031 | 103,714 | 69,902 |
Balance Sheet
(in thousands, except per share data)
| March 31, – 2026 | June 30, – 2025 | ||
|---|---|---|---|
| Condensed Consolidated Balance Sheets Data: | Cash and cash equivalents | 11,236 | 94,107 |
| Condensed Consolidated Balance Sheets Data: | Investments in marketable debt securities | 109,032 | 73,751 |
| Condensed Consolidated Balance Sheets Data: | Working capital | 114,345 | 159,233 |
| Condensed Consolidated Balance Sheets Data: | Total assets | 125,459 | 175,490 |
| Condensed Consolidated Balance Sheets Data: | Accumulated deficit | -460,951 | -403,856 |
| Condensed Consolidated Balance Sheets Data: | Total stockholders’ equity | 116,834 | 162,127 |
Full release
Forward-Looking Statements
This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect,"
"intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. These forward-looking statements include, but are not limited to, the predictive nature of the CGM data as it relates to the potential efficacy of ersodetug in treating hypoglycemia, the ability of the Company to provide study reports and analysis datasets for the FDA’s independent evaluation, the persuasiveness of the study reports and analysis datasets and the possibility of FDA agreeing to advance the congenital HI program based on those study reports and analysis datasets notwithstanding the lack of statistical significance in the sunRIZE study. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.
Rezolute Contacts:
Christen Baglaneas cbaglaneas@rezolutebio.com
508-272-6717
Carrie McKim cmckim@rezolutebio.com
336-608-9706
Rezolute, Inc.
Condensed Consolidated Financial Statements Data
(in thousands, except per share data)